These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31592652)

  • 21. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Caffeine enhances the anti-tumor effect of 5-fluorouracil via increasing the production of reactive oxygen species in hepatocellular carcinoma.
    Wang Z; Gu C; Wang X; Lang Y; Wu Y; Wu X; Zhu X; Wang K; Yang H
    Med Oncol; 2019 Oct; 36(12):97. PubMed ID: 31664534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polyamine-Targeting Gefitinib Prodrug and its Near-Infrared Fluorescent Theranostic Derivative for Monitoring Drug Delivery and Lung Cancer Therapy.
    Song X; Han X; Yu F; Zhang X; Chen L; Lv C
    Theranostics; 2018; 8(8):2217-2228. PubMed ID: 29721074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Azo-based near-infrared fluorescent theranostic probe for tracking hypoxia-activated cancer chemotherapy in vivo.
    Ding N; Li Z; Tian X; Zhang J; Guo K; Wang P
    Chem Commun (Camb); 2019 Oct; 55(87):13172-13175. PubMed ID: 31620737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen receptor (AR)/miR-520f-3p/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer stem cells phenotype.
    Xiao Y; Sun Y; Liu G; Zhao J; Gao Y; Yeh S; Gong L; Chang C
    Cancer Lett; 2019 Mar; 444():175-187. PubMed ID: 30448543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma.
    Zhu D; Wu S; Hu C; Chen Z; Wang H; Fan F; Qin Y; Wang C; Sun H; Leng X; Kong D; Zhang L
    Acta Biomater; 2017 Aug; 58():399-412. PubMed ID: 28627436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-time near-infrared bioimaging of a receptor-targeted cytotoxic dendritic theranostic agent.
    Wu J; Zhou Y; Li S; Qu D; Zhu WH; Tian H
    Biomaterials; 2017 Mar; 120():1-10. PubMed ID: 28011190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multifunctional hybrid micelles with tunable active targeting and acid/phosphatase-stimulated drug release for enhanced tumor suppression.
    Liu X; Li Y; Tan X; Rao R; Ren Y; Liu L; Yang X; Liu W
    Biomaterials; 2018 Mar; 157():136-148. PubMed ID: 29268144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Artemin is hypoxia responsive and promotes oncogenicity and increased tumor initiating capacity in hepatocellular carcinoma.
    Zhang M; Zhang W; Wu Z; Liu S; Sun L; Zhong Y; Zhang X; Kong X; Qian P; Zhang H; Lobie PE; Zhu T
    Oncotarget; 2016 Jan; 7(3):3267-82. PubMed ID: 26675549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and biological activity of novel 5-fluoro-2'-deoxyuridine phosphoramidate prodrugs.
    Freel Meyers CL; Hong L; Joswig C; Borch RF
    J Med Chem; 2000 Nov; 43(22):4313-8. PubMed ID: 11063625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer cell membrane-coated magnetic nanoparticles for MR/NIR fluorescence dual-modal imaging and photodynamic therapy.
    Li J; Wang X; Zheng D; Lin X; Wei Z; Zhang D; Li Z; Zhang Y; Wu M; Liu X
    Biomater Sci; 2018 Jun; 6(7):1834-1845. PubMed ID: 29786715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor.
    Kumar R; Kim EJ; Han J; Lee H; Shin WS; Kim HM; Bhuniya S; Kim JS; Hong KS
    Biomaterials; 2016 Oct; 104():119-28. PubMed ID: 27449948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Smart Theranostic Prodrug System Activated by Reactive Oxygen Species for Regional Chemotherapy of Metastatic Cancer.
    Liu L; Liu F; Liu D; Yuan W; Zhang M; Wei P; Yi T
    Angew Chem Int Ed Engl; 2022 Mar; 61(12):e202116807. PubMed ID: 35068033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxia-Responsive Golgi-Targeted Prodrug Assembled with Anthracycline for Improved Antitumor and Antimetastasis Efficacy.
    Guo C; Wu M; Guo Z; Zhang R; Wang Z; Peng X; Dong J; Sun X; Zhang Z; Xiao P; Gong T
    ACS Nano; 2023 Dec; 17(24):24972-24987. PubMed ID: 38093174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Noncovalent Theranostic Prodrug for Hypoxia-Activated Drug Delivery and Real-Time Tracking.
    Zhao XB; Gao K; Shi YP
    Anal Chem; 2021 Nov; 93(45):15080-15087. PubMed ID: 34743509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reconsidering azobenzene as a component of small-molecule hypoxia-mediated cancer drugs: A theranostic case study.
    Verwilst P; Han J; Lee J; Mun S; Kang HG; Kim JS
    Biomaterials; 2017 Jan; 115():104-114. PubMed ID: 27886551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nitroreductase-Activatable Theranostic Molecules with High PDT Efficiency under Mild Hypoxia Based on a TADF Fluorescein Derivative.
    Liu Z; Song F; Shi W; Gurzadyan G; Yin H; Song B; Liang R; Peng X
    ACS Appl Mater Interfaces; 2019 May; 11(17):15426-15435. PubMed ID: 30945838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A NIR fluorescent smart probe for imaging tumor hypoxia.
    Hettie KS; Klockow JL; Moon EJ; Giaccia AJ; Chin FT
    Cancer Rep (Hoboken); 2021 Oct; 4(5):e1384. PubMed ID: 33811473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and biological activity of N-2,3-dihydroxypropyl-N-4-chlorobutyl nucleoside phosphoramidate prodrugs.
    Wu W; Borch RF
    Mol Pharm; 2006; 3(4):451-6. PubMed ID: 16889439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting and Treatment of Tumor Hypoxia by Newly Designed Prodrug Possessing High Permeability in Solid Tumors.
    Ikeda Y; Hisano H; Nishikawa Y; Nagasaki Y
    Mol Pharm; 2016 Jul; 13(7):2283-9. PubMed ID: 27187083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.